Clinical Usefulness and Optimal Harvesting of Peripheral Blood Stem Cells Mobilized by High Dose Cyclophosphamide and Recombinant Human GM-CSF
The existence of normal hematopoietic stem cells in the peripheral blood of mammals has been known for a quarter of a century ; however, they were first used to reconstitute the bone marrow of patients after myeloablative chemoradiotherapy only 4–5 years ago [2–6]. After obtaining proof that circulating progenitors are capable of complete and long-lasting hematopoietic reconstitution, clinicians have increasingly employed them as an alternative to bone marrow-derived stem cells. By the end of 1989, over 200 autotransplants of peripheral blood stem cells had been reported or published.
KeywordsPeripheral Blood Stem Cell Bone Marrow Involvement Peripheral Blood Stem Cell Transplant Optimal Harvesting Peripheral Blood Progenitor Cell
Unable to display preview. Download preview PDF.
- 2.Juttner CA, To LB, Haylock DN, et al. (1985) Circulating autologous stem cell collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete hematopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Hematol 61: 739–745CrossRefGoogle Scholar
- 3.Reifers J, Bernard P, David B, et al. (1986) Successful autologous transplantation with peripheral blood hematopoietic cells in a patient with acute leukemia. Exp Hematol 14: 312–315Google Scholar
- 7.Storb R (1989) Bone marrow transplantation. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, chap 66, 3rd edn. Lippincott, Philadelphia, pp 2474–2489Google Scholar